Lifestance Health Group (LFST) Q4 2024 earnings summary

Executive summary

• Achieved 2024 revenue of $1.25 billion, up 19% year-over-year, with Q4 revenue of $325.5 million, up 16% year-over-year.

• Adjusted EBITDA more than doubled to $119.7 million for 2024 (9.6% margin), with Q4 Adjusted EBITDA at $32.8 million (10.1% margin).

• Clinician base grew 12% year-over-year to 7,424, with 779 net additions; visit volumes increased 15% to 7.9 million for the year.

• Net loss narrowed to $7.1 million in Q4 and $57.4 million for the year, a significant improvement from 2023.

• Leadership transition: Dave Bourdon appointed CEO, Ken Burdick to become Executive Chairman, and Ryan McGroarty named new CFO.

Financial highlights

• Q4 Center Margin was $109.4 million (33.6% of revenue), up 31% year-over-year; full year Center Margin was $402.4 million (32.2% of revenue).

• Total revenue per visit in Q4 was $160.1, up from $157.4 in Q4 2023.

• Free cash flow in Q4 was $56 million, with $85.7 million for the year.

• Ended Q4 with $154.6 million in cash and net long-term debt of $280 million.

• Cash from operations was $107.3 million for 2024, with $62.3 million generated in Q4.

Outlook and guidance

• 2025 guidance: revenue of $1.4–1.44 billion, Center Margin of $440–464 million, Adjusted EBITDA of $130–150 million, all based on organic growth.

• Q1 2025 guidance: revenue of $320–340 million, Center Margin of $100–114 million, Adjusted EBITDA of $27–33 million.

• Plans for 25–30 de novo center openings in 2025; M&A potential not included in guidance.

• Expect flat revenue per visit in 2025 due to payer rate pressure, offset by G&A leverage.

• 2026 outlook: expect mid-teens revenue growth, margin expansion, and positive net income and EPS.